Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Phase I Trial
PURPOSE: CD40 agonists activate dendritic cells (DCs) and promote T-cell antitumor immunity, but clinical development has been limited by systemic toxicity and incomplete understanding of determinants of response. In this phase I study (NCT05126472), we evaluated the safety, preliminary clinical activity, and spatial immune correlates of response to intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients received weekly intravesical instillations for 3 weeks, with retreatment at weeks 13 and 25 based on disease status. Primary objectives were safety, tolerability, and determination of the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Secondary endpoints included pharmacokinetics and preliminary clinical activity. Exploratory endpoints including multiplex spatial profiling on tumor specimens to define correlates of response. RESULTS: Intravesical 2141-V11 was well tolerated, and the MTD was not reached. The RP2D was established at 70 mg. Preliminary clinical activity was observed in 40% of patients, with a median response duration of 20 months. Clinical response was associated with distinct organization of tertiary lymphoid structures, characterized by the presence of DC-CXCL13+ CD4+ and CD8+ T cell triads. Following treatment, responders exhibited decreased proximity between DCs and regulatory T cells (Tregs), whereas non-responders exhibited increased DC-Treg proximity. CONCLUSIONS: Intravesical 2141-V11 demonstrated a favorable safety profile and preliminary antitumor activity. Spatial profiling revealed immune-cell organizations associated with clinical response, identifying candidate biomarkers and potential strategies for therapeutic combinations. These findings support further clinical evaluation of intravesical 2141-V11 in phase II studies.
Authors
- Jeffrey V. Ravetch (ORCID: https://orcid.org/0000-0003-2024-9041)
- Hikmat A Al‐Ahmadie (ORCID: https://orcid.org/0000-0002-2938-6627)
- Jeffrey L. Wong (ORCID: https://orcid.org/0000-0002-3521-4012)
- Timothy F. Donahue (ORCID: https://orcid.org/0000-0002-0932-2968)
- Juan Carlos Angulo-Lozano (ORCID: https://orcid.org/0000-0002-2995-7565)
- Lucas Blanchard (ORCID: https://orcid.org/0000-0001-6942-7086)
- Karissa A. Whiting (ORCID: https://orcid.org/0000-0002-4683-1868)
- David A. Knorr (ORCID: https://orcid.org/0000-0002-0766-8914)
- Eugene J. Pietzak (ORCID: https://orcid.org/0000-0002-5121-5701)
- Venkatraman Seshan (ORCID: https://orcid.org/0000-0002-9258-2698)
- Jonathan E. Rosenberg (ORCID: https://orcid.org/0000-0003-2637-4249)
- Melissa McCarter (ORCID: https://orcid.org/0009-0005-7859-8588)
- Benjamin D. Greenbaum (ORCID: https://orcid.org/0000-0001-6153-8793)
- Juan Carlos Osorio (ORCID: https://orcid.org/0000-0001-8090-1551)
- Ved P. Sharma (ORCID: https://orcid.org/0000-0001-9998-5070)
- Bernard H. Bochner (ORCID: https://orcid.org/0000-0003-0846-0848)
- Steven Grudman (ORCID: https://orcid.org/0009-0002-2504-9575)
- Morgan Tomberlin (ORCID: https://orcid.org/0009-0000-9979-0556)
- Ning Yao (ORCID: https://orcid.org/0009-0006-9658-7142)
- Andrew Mijacika (ORCID: https://orcid.org/0009-0007-0464-9842)
- Syed M. Alam (ORCID: https://orcid.org/0000-0001-7854-2967)
- Jessica Pfau (ORCID: https://orcid.org/0009-0000-1095-7103)
- Robert Smith (ORCID: https://orcid.org/0009-0004-2228-8815)
- Ali Ghasemzadeh (ORCID: https://orcid.org/0009-0003-7779-4881)
- Carlo Sevilla (ORCID: https://orcid.org/0009-0006-6051-5358)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Rockefeller University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-3256
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- V Foundation for Cancer Research